James Green

James Green is a seasoned executive in the biotech and pharmaceutical industries, currently serving as Chief Executive Officer of Vogenx, Inc. since 2022, focusing on therapeutics for gastrointestinal and metabolic diseases. Green has held various leadership roles, including Chief Executive Officer at Avolynt, Inc. and BHV Pharma, and Chairman & Chief Executive Officer at Islet Sciences, Inc. Additionally, Green has experience in corporate finance and mergers and acquisitions as Director of Deal Finance and M&A at GlaxoSmithKline Pharma GmbH. Notable board affiliations include positions at Osprey32, Inc. and the Pharmacogenetics for Every Nation Initiative. Green holds an MBA from the University of Pittsburgh Katz Graduate School of Business and a BBA from the University of North Florida.